Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334422 | 1.00 | HPGD (0.46) | HPGDKCNA5POLBGFERL3MBTL1 | |
| SCHEMBL6336890 | 0.82 | HPGD (0.48) | HPGDKCNA5POLBGFERL3MBTL1 | |
| SCHEMBL6335936 | 0.81 | MEN1 (0.44) | HPGDPOLBL3MBTL1ALDH1A1LMNA | |
| SCHEMBL6334486 | 0.80 | ADORA1 (0.38) | LMNACYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6334410 | 0.79 | HPGD (0.45) | HPGDKCNA5POLBGFERL3MBTL1 | |
| SCHEMBL6334408 | 0.79 | HPGD (0.45) | HPGDKCNA5POLBGFERL3MBTL1 | |
| SCHEMBL6334571 | 0.76 | P2RX7 (0.46) | ALDH1A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6491144 | 0.74 | HPGD (0.38) | HPGDKCNA5POLBGFERL3MBTL1 | |
| SCHEMBL6332661 | 0.72 | PIK3CD (0.40) | CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6404299 | 0.71 | BRAF (0.37) | L3MBTL1ALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1330657-C | Piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | CN | claimed |
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | claimed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | claimed |
| CN-1434827-A | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | claimed |
| CN-1330657-C | Piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | CN | disclosed |
| CN-1436232-A | Variants with altered properties | NOVOZYMES AS (DK) | 2003-08-13 | — | — | CN | disclosed |
| CN-1434827-A | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | HPGD 416/4885KCNA5 115/4885POLB 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.